Department of Orthopedic, Mayo Clinic, Rochester, MN 55905, USA.
Curr Oncol. 2024 Sep 24;31(10):5730-5736. doi: 10.3390/curroncol31100425.
Reconstruction of the abductor mechanism remains a primary challenge with contemporary proximal femoral replacement (PFR) surgery. Previously, techniques such as trochanteric preservation or direct repair to the implant have been described; however, these strategies are limited in their ability to tension the repair and reattach other muscles of the hip girdle. The aim of this study was to evaluate the outcomes of patients undergoing oncologic PFR using a novel technique of mesh augmentation for soft tissue repair.
We reviewed 18 (mean age 64 years; 8 female: 10 male) consecutive patients undergoing PFR with Marlex mesh augmentation between 2018 and 2023 at a single institution. The most common indication was metastatic disease (n = 13). The mean follow-up in the 14 surviving patients was 27 months (range 12-34).
All patients were ambulatory at final follow-up. There were no post-operative dislocations, infections, or wound issues. At the final follow-up, the mean total MSTS score was 77%.
Mesh augmentation of PFRs allowed for adequate soft tissue tensioning and muscular attachment to the body of the implant. In our series, this technique was durable, with no dislocations and no mesh-related complications. In summary, mesh augmentation of PFRs may be considered during reconstruction for oncologic indications.
在当代股骨近端置换术(PFR)中,重建外展肌机制仍然是一个主要挑战。以前,已经描述了诸如转子保留或直接修复植入物等技术;然而,这些策略在拉紧修复和重新连接髋关节其他肌肉的能力方面存在局限性。本研究旨在评估使用 Marlex 网片增强软组织修复的新型技术对接受肿瘤性 PFR 的患者的治疗结果。
我们回顾了 2018 年至 2023 年间在一家机构接受 PFR 并使用 Marlex 网片增强的 18 例(平均年龄 64 岁;8 名女性:10 名男性)连续患者。最常见的适应证是转移性疾病(n = 13)。14 例存活患者的平均随访时间为 27 个月(范围 12-34 个月)。
所有患者在最终随访时均可行走。无术后脱位、感染或伤口问题。在最终随访时,平均总 MSTS 评分为 77%。
PFR 的网片增强允许充分拉紧软组织并将肌肉附着在植入物的主体上。在我们的系列中,这种技术是持久的,没有脱位和与网片相关的并发症。总之,对于肿瘤性适应证,在重建时可以考虑使用 PFR 的网片增强。